GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of GLP-1 Receptor Agonists and SGLT2 Inhibitors Versus Monotherapy in Patients with MASLD and Type 2 Diabetes: Insights from Three Target Trial Emulations

  • By

  • Mohanad A. Alkuwaiti

  • Faisal A. Al-Harbi

  • Ahmed K. Alsaif

  • Ziyad M. AlSughayyir

  • Rayan Saleh Alsaud

  • Mohammed N. Aljabr

  • Ahmad K. Alanazi

  • Ahmad A. Alosaily

  • Abdulrhman K. Alabdulqader

  • Hamza Almusabeh

  • Rayyan F. Altemani

  • Ahmed Y. Azzam

  • July 13, 2026

Share

Original Source(s)

GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations

  • by Mohanad A. Alkuwaiti, Faisal A. Al-Harbi, Ahmed K. Alsaif, Ziyad M. AlSughayyir, Rayan Saleh Alsaud, Mohammed N. Aljabr, Ahmad K. Alanazi, Ahmad A. Alosaily, Abdulrhman K. Alabdulqader, Hamza Almusabeh, Rayyan F. Altemani, Ahmed Y. Azzam

  • July 13, 2026

Related Content

Risk factors for inferior right hepatic vein occlusion following right lobe living donor liver transplantation: a single-center experience with 240 cases

Imaging features, diagnosis, and clinical management of hepatic involvement in hereditary hemorrhagic telangiectasia: a case series report and literature review

Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions